SCHOTT Pharma AG & Co. KGaA

SCHOTT PHARMA AG & CO KGAA's next confirmed earnings release is scheduled for December 10, 2026.

As of June 30, 2026, SCHOTT PHARMA AG & CO KGAA has 601.15M shares outstanding.

As of June 30, 2026, SCHOTT PHARMA AG & CO KGAA maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, SCHOTT PHARMA AG & CO KGAA posted a return on equity (ROE) of 14.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.24 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.48, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.06, useful for judging operating efficiency across full business cycles. The company generates approximately 241,604.01 in revenue per employee across its workforce of 4,811.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.13 indicates how many times SCHOTT PHARMA AG & CO KGAA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SCHOTT PHARMA AG & CO KGAA recorded 43.73M in income tax expense. That works out to an effective tax rate of 21.83, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 200.33M, leaving 156.03M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 14, 2026, SCHOTT PHARMA AG & CO KGAA's stock has declined approximately 14.38% over the past 52 weeks.

Over the twelve months ended June 30, 2026, SCHOTT PHARMA AG & CO KGAA generated 1.16B in revenue and converted that into 156.03M in net income, yielding earnings per share of 0.26. EBITDA reached 311.45M, while operating income came in at 192.92M.

These figures are as of June 30, 2026. Total book value stands at 1.14B, with working capital of 311.16M providing operational flexibility.

SCHOTT PHARMA AG & CO KGAA produced 220.57M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -157.64M in capital expenditures, free cash flow totaled 62.93M - equivalent to 0.11 per share.

Over the twelve months ended June 30, 2026, SCHOTT PHARMA AG & CO KGAA posted a gross margin of 31.19, reflecting its pricing power and cost economics. The operating margin of 16.60 and net profit margin of 13.42 provide insight into operational efficiency.